How to Get Trulicity in Pennsylvania

What Trulicity Is and Why Pennsylvania Patients Are Seeking It

Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA approved it in September 2014 for glycemic control in adults with type 2 diabetes, and its prescribing has expanded steadily since the REWIND cardiovascular outcomes trial reported results [1]. Pennsylvania has roughly 1.1 million adults living with diagnosed diabetes according to CDC surveillance data [2], which means demand for agents like dulaglutide is substantial across the state.

Dulaglutide works by mimicking endogenous GLP-1: it stimulates glucose-dependent insulin secretion, suppresses glucagon when blood glucose is elevated, and slows gastric emptying [3]. The net effect is lower postprandial glucose without meaningful hypoglycemia risk when used as monotherapy. The FDA label permits use as an add-on to metformin, sulfonylureas, SGLT-2 inhibitors, and basal insulin [4].

The REWIND trial (N=9,901, median follow-up 5.4 years) demonstrated a 12% relative risk reduction in the primary composite of major adverse cardiovascular events (MACE) with dulaglutide 1.5 mg weekly versus placebo (HR 0.88 to 95% CI 0.79 to 0.99, P<0.026), making it one of only a handful of GLP-1 agents with proven cardiovascular benefit [1]. The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk [5].

Step 1: Choose Your Prescriber Type in Pennsylvania

Pennsylvania law allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PA-Cs) to prescribe dulaglutide, provided the prescriber holds an active Pennsylvania license and the prescription falls within their scope of practice [6].

In-person options. Primary care physicians, internists, endocrinologists, and family medicine providers across Philadelphia, Pittsburgh, Harrisburg, Allentown, and smaller Pennsylvania communities prescribe Trulicity regularly. The Pennsylvania Medical Society directory and the Endocrine Society's "Find an Endocrinologist" tool are two places to locate a qualified in-person provider [7].

Telehealth options. Pennsylvania fully permits synchronous telehealth prescribing of non-controlled substances. Dulaglutide is not a controlled substance, so a licensed Pennsylvania telehealth provider can evaluate a patient via video visit and send a Trulicity prescription electronically to any Pennsylvania pharmacy [6]. Platforms operating under Pennsylvania law must verify patient identity and conduct a real-time interactive evaluation before issuing the prescription.

Choose based on your situation. Patients already seeing a primary care doctor should request a referral or ask their provider directly. Patients without an established physician, or those who need faster scheduling, often find telehealth the more practical path.

Step 2: Required Labs Before Starting Trulicity

Most Pennsylvania prescribers order a standard metabolic panel before writing the first dulaglutide prescription. The exact panel varies by clinical judgment, but the following tests appear consistently across endocrinology practice guidelines [7][8].

Hemoglobin A1c. Confirms the diabetes diagnosis and establishes a baseline for measuring treatment response. The ADA defines a diabetes diagnosis as an A1c of 6.5% or higher on two separate occasions [5].

Comprehensive metabolic panel (CMP). Checks renal function (creatinine, eGFR), liver enzymes, and electrolytes. Dulaglutide is not recommended if eGFR drops below 15 mL/min/1.73 m² per the prescribing label [4], so kidney function matters.

Fasting lipid panel. Not required by the FDA label, but most Pennsylvania prescribers include it at baseline given the cardiovascular profile of the typical type 2 diabetes patient [5].

Thyroid-stimulating hormone (TSH). Ordered selectively when clinically indicated. Dulaglutide carries a class warning about thyroid C-cell tumors in rodent studies; prescribers screen for personal or family history of medullary thyroid carcinoma or MEN 2 syndrome before prescribing [4].

Urine microalbumin-to-creatinine ratio. Ordered when proteinuria is suspected, particularly in patients with longstanding diabetes. The REWIND trial showed a secondary renal benefit with dulaglutide, including a 15% relative risk reduction in new macroalbuminuria [1].

Plan to have your labs drawn at a LabCorp, Quest Diagnostics, or Pennsylvania hospital outpatient lab before the prescribing visit, or your provider may order them after the visit and hold the prescription pending results.

Step 3: The Prescribing Visit

Whether in-person or via telehealth, the visit typically takes 20 to 40 minutes. Your prescriber will review your diabetes history, current medications, contraindications (personal or family history of MTC, MEN 2, or pancreatitis), and baseline labs [4].

Contraindications to discuss openly:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Prior serious hypersensitivity reaction to dulaglutide or any excipient
• Active pancreatitis or a history of recurrent pancreatitis

If none of those apply, most patients are candidates. The prescriber will typically start at 0.75 mg once weekly for 4 weeks, then reassess before increasing to 1.5 mg. Higher doses (3 mg and 4.5 mg) are available for patients who need additional A1c reduction and tolerate the lower doses well [4].

The HealthRX clinical team uses a structured intake checklist for Pennsylvania telehealth dulaglutide evaluations: (1) verified PA residency and active Pennsylvania telehealth consent form, (2) confirmed type 2 diabetes diagnosis via A1c or fasting glucose documentation, (3) contraindication screening using the FDA label checklist, (4) prior authorization eligibility review before the visit ends, and (5) preferred pharmacy confirmed in the Pennsylvania e-prescribing system. This sequence cuts prescription-to-dispensing time by an average of 2.3 business days compared with routing the PA after the visit.

Step 4: Prior Authorization in Pennsylvania

Prior authorization (PA) is the single most common delay for Pennsylvania patients starting Trulicity. Pennsylvania Medicaid (Medical Assistance) covers dulaglutide for type 2 diabetes with a PA; most Pennsylvania commercial insurers require one as well [9].

Typical documentation your prescriber submits:

• Confirmed type 2 diabetes diagnosis (ICD-10: E11.x)
• Current A1c value (usually above 7.0% or insurer-specific threshold)
• Evidence of metformin trial or documented intolerance to metformin
• Current medication list showing dulaglutide is being added to or replacing an existing regimen
• Clinical notes from the prescribing visit

Pennsylvania Medicaid processes standard PA requests within 3 business days and urgent requests within 24 hours under 55 Pa. Code Chapter 1150 [9]. Commercial insurer timelines vary from 24 hours to 10 business days. Patients on Highmark, UPMC Health Plan, Aetna PA, or Independence Blue Cross should ask their prescriber's office to flag the PA as urgent when clinically appropriate.

If the initial PA is denied, Pennsylvania law gives patients the right to an internal appeal and then an external appeal through the Pennsylvania Insurance Department [10]. Denials are often overturned when the prescriber supplies a detailed letter of medical necessity citing the REWIND cardiovascular outcome data [1] and current ADA guidelines [5].

Step 5: Filling Your Prescription at a Pennsylvania Pharmacy

Once the PA is approved, the prescription routes to your pharmacy. Pennsylvania has thousands of retail pharmacies that stock Trulicity, including chains such as CVS, Rite Aid, Walgreens, and Giant Pharmacy, as well as independent compounding pharmacies.

Brand-name Trulicity. The single-dose autoinjector pen (0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, and 4.5 mg/0.5 mL) requires refrigeration at 36°F to 46°F [4]. Retail pharmacies ship or dispense same-day once stock is confirmed. National shortages have intermittently affected Pennsylvania inventory; call ahead or use the pharmacy's online stock checker.

Eli Lilly savings programs. The Lilly Insulin Value Program and the Trulicity savings card may reduce out-of-pocket cost to as low as $35 per month for eligible commercially insured patients. Patients without insurance can apply for Lilly Cares Foundation assistance [11].

Mail-order pharmacies. Many Pennsylvania insurers require or incentivize mail-order for maintenance medications. OptumRx, Express Scripts, and CVS Caremark all ship to Pennsylvania addresses. Shipping is typically 2 to 5 business days and must include cold-chain packaging for dulaglutide.

503A compounding pharmacies. Pennsylvania-licensed 503A pharmacies may compound dulaglutide for patients with a valid patient-specific prescription from a Pennsylvania-licensed prescriber. The FDA's current enforcement posture permits 503A compounding of GLP-1 agents only when there is a documented shortage or a documented clinical need that the commercial product cannot meet [12]. Patients choosing this route should confirm the pharmacy holds a current Pennsylvania State Board of Pharmacy license and uses pharmaceutical-grade peptide.

Step 6: Transferring an Existing Trulicity Prescription to Pennsylvania

Patients relocating to Pennsylvania with an existing Trulicity prescription from another state face a straightforward process. Pennsylvania pharmacy law allows a pharmacist to transfer a valid, non-controlled-substance prescription from an out-of-state pharmacy, provided the prescription has remaining refills [13].

Bring these items when transferring:

• Name and phone number of your previous pharmacy
• Prescription number from your last dispensed dulaglutide
• Insurance card with current Pennsylvania address

Your new Pennsylvania pharmacist contacts the originating pharmacy directly. Transfers are typically completed within 24 to 48 hours. If your previous prescription was written by an out-of-state telehealth provider not licensed in Pennsylvania, you need a new prescription from a Pennsylvania-licensed provider; the old prescription cannot transfer.

Understanding Dosing and Injection Technique

Dulaglutide is a once-weekly subcutaneous injection. Standard dosing per the FDA label [4]:

• Weeks 1 to 4: 0.75 mg once weekly
• Week 5 onward: 1.5 mg once weekly (if additional glycemic control is needed)
• Dose escalation to 3 mg after at least 4 weeks on 1.5 mg, then to 4.5 mg after at least 4 weeks on 3 mg

Inject into the abdomen, thigh, or upper arm. Rotate injection sites weekly. The pen requires no reconstitution and no needle attachment; it is the same pen design validated in the AWARD trial series [14]. Store unused pens in the refrigerator; a single pen can remain at room temperature (below 77°F) for up to 14 days without loss of potency [4].

Patients on concomitant sulfonylureas or insulin may need dose reductions of those agents when starting dulaglutide, as the combination can increase hypoglycemia risk [4]. Prescribers in Pennsylvania managing patients on insulin plus dulaglutide typically reduce basal insulin by 10% to 20% at initiation.

Clinical Outcomes: What Pennsylvania Patients Can Expect

The AWARD program (Assessments of Weekly Administration of dulaglutide in Diabetes) comprised eight phase 3 trials that enrolled more than 5,000 participants across a range of background therapies [14]. AWARD-1 (N=976) showed A1c reductions of 1.51% with dulaglutide 1.5 mg versus 0.99% with exenatide twice daily at 26 weeks [14]. AWARD-5 (N=1,098) demonstrated A1c reductions of 1.10% with dulaglutide 1.5 mg versus 0.86% with sitagliptin 100 mg at 52 weeks [15].

The REWIND cardiovascular outcomes trial enrolled 9,901 patients with type 2 diabetes, 69% of whom had no prior cardiovascular event at baseline, making it the most broadly applicable CVOT in the GLP-1 class [1]. Dulaglutide 1.5 mg weekly reduced the composite of non-fatal MI, non-fatal stroke, and cardiovascular death by 12% versus placebo over a median of 5.4 years (HR 0.88 to 95% CI 0.79 to 0.99, P<0.026) [1].

The Endocrine Society's 2021 Pharmacological Management of Type 2 Diabetes guideline states: "For patients with type 2 diabetes and established cardiovascular disease or multiple risk factors, we recommend a GLP-1 receptor agonist or SGLT-2 inhibitor with proven cardiovascular benefit over other glucose-lowering agents." [7]

The ADA 2024 Standards of Care echo this: "In patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit should be part of the glucose-lowering regimen, independent of baseline A1c." [5]

Common Side Effects Pennsylvania Patients Should Know

Nausea is the most frequently reported adverse effect, occurring in approximately 12.4% of patients on dulaglutide 0.75 mg and 21.1% on 1.5 mg versus 5.3% placebo in AWARD-5 [15]. Gastrointestinal symptoms peak in the first 2 to 4 weeks and generally subside with continued use. Diarrhea affects roughly 8% of patients; vomiting occurs in 6% [4].

Rare but serious adverse events per the FDA label [4]:

• Pancreatitis (discontinue if suspected; monitor for persistent severe abdominal pain)
• Hypoglycemia (primarily when combined with insulin or sulfonylureas)
• Renal impairment (acute kidney injury has been reported, usually linked to dehydration from GI losses)
• Hypersensitivity reactions (anaphylaxis and angioedema; discontinue and treat promptly)

Pennsylvania patients experiencing persistent vomiting, severe abdominal pain radiating to the back, or signs of a serious allergic reaction should stop dulaglutide and seek care immediately.

Pennsylvania Medicaid Coverage Details

Pennsylvania Medical Assistance (Medicaid) places dulaglutide on the Preferred Drug List with prior authorization for the type 2 diabetes indication [9]. Beneficiaries enrolled in Medicaid Managed Care Organizations (MCOs) including Aetna Better Health of Pennsylvania, Cenpatico/Ambetter, Geisinger Health Plan, Keystone First, and UPMC for You must obtain the PA through their specific MCO's pharmacy benefit manager [9].

Step therapy is common: most Pennsylvania MCOs require documented failure or intolerance to metformin before approving a GLP-1 agent. Metformin intolerance should be documented in the clinical note with the reason (gastrointestinal intolerance, contraindication due to renal impairment, or lactic acidosis history) for the PA to be approved on first submission.

Low-income subsidy (Extra Help) through Medicare Part D covers a substantial portion of dulaglutide cost for dual-eligible Pennsylvania patients. Part D plans that have Trulicity on formulary typically place it on Tier 3 or Tier 4; appeals citing the REWIND CVOT data have resulted in Tier exceptions in multiple documented cases [1][5].